Lipid Nanoparticles Immunogenicity and Toxicity on December 06-08, 2022 in Boston, United States

Enhance Your Prediction of PKPD, Accurate Dosing Regime and Immuno-Modulation of LNP for Long-Term Patient Safety and Potency

Following the success of LNP-mRNA vaccines, we have seen an influx of novel types of lipids based nanocarriers over the last 12 months, progress has been made to minimize immuno-toxicity challenges – from maximizing therapeutic window to fine-tuning the immune response.

The highly anticipated Lipid Nanoparticle Immunogenicity and Toxicity Summit takes place this December to unite 80+ senior leaders as the definitive meeting for clinical pharmacology, immunogenicity, bioanalytical development leaders to stay at the forefront, arming you with practical takeaways and lessons learned.

Across 3 days, we will delve into:

HW220702 LNP Immunogenicity and Toxicity logo Favicon

Immunomodulation strategies to increase the therapeutic window

HW220702 LNP Immunogenicity and Toxicity logo Favicon

Translatable preclinical models to revolutionize clinical relevancy

HW220702 LNP Immunogenicity and Toxicity logo Favicon

Dosing considerations dependent on your disease indication, route of administration and patient group for improved safety

And much more!

Hear the latest insights and case studies to optimize your prediction of PKPD, accurate dosing regime and immuno-modulation of LNP for long-term patient safety and potency.

Across 3 days, with over 6 hours of networking, this is your must-attend summit in 2022, to join the likes of AstraZeneca, Bristol Myers Squibb, NanoVation Therapeutics, Vertex Pharmaceuticals to lay the foundation for robust immunotoxicity protocols, propelling your novel pipeline growth.

URLs:

Tickets: https://go.evvnt.com/1289158-2?pid=10008

Brochure: https://go.evvnt.com/1289158-3?pid=10008

Prices:

Conference + 2 Workshops - Drug Developer Pricing: USD 4297.00,

Conference + 1 Workshop - Drug Developer Pricing: USD 3648.00,

Conference Only - Drug Developer Pricing: USD 2999.00,

Conference + 2 Workshops - Academic Pricing: USD 3697.00,

Conference + 1 Workshop - Academic Pricing: USD 3148.00,

Conference Only - Academic Pricing: USD 2599.00,

Conference + 2 Workshops - Service Provider Pricing: USD 5097.00,

Conference + 1 Workshop - Service Provider Pricing: USD 4348.00,

Conference Only - Service Provider Pricing: USD 3599.00

Speakers: Vibha Jawa, Executive Director, Bristol Myers Squibb, Tao Niu, Associate Director, Modeling and Simulations, Vertex Pharmaceuticals, Laurent Malherbe, Senior Director, Eli Lilly and Company, Christophe Quéva, Chief Scientific Officer, Oncorus, Philippe Collin, Director - Delivery Systems, Clinical Pharmacology and Safety Sciences, AstraZeneca, Joshua DiNapoli, Global Project Head - mRNA Platform Development, Sanofi Pasteur, Jayesh Kulkarni, Chief Scientific Officer, NanoVation Therapeutics, Marina Dobrovolskaia, Director of Operations, Nanotechnology Characterization Lab, Frederick National Laboratory for Cancer Research, Kalina Paunovska, Co-Founder, Nava Therapeutics, Kirill Afonin, Professor, University of North Carolina, Cris Kamperschroer, Distinguished Scientist, Sanofi, Rakesh Dixit, President and CEO, Bionavigen, Dr Neill Liptrott, Reader in Pharmacology and Immunocompatibility, University of Liverpool, Peter Bedocs, Senior Scientist, Defense and Veterans Center for Integrative Pain Management, Zohreh Amoozgar, Principal Scientist, Lab Head, Sanofi, Hamideh Parhiz, Research Assistant Professor, UPENN, Esmaiel Jabbari, Professor, University of South Carolina, Botond Z. Igyártó, Associate Professor, Thomas Jefferson University, Janos Szebeni, Full Professor, Director of Nanomedicine Research and Education Center, Semmelweis University, Seyed Hossein Kiaie, Faculty of Pharmacy Tabriz, University of Medical Sciences, Swayam Prabha, Associate Professor, Department of Pharmacology, Lewis Katz School of Medicine, Temple University, Heather Denroche, Director of Preclinical Development, Integrated Nanotherapeutics Inc.

Time: 09:00 to 16:00